Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN HYDROCORTISONE versus EMFLAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN HYDROCORTISONE versus EMFLAZA.
CHLOROMYCETIN HYDROCORTISONE vs EMFLAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromycetin (chloramphenicol) is a bacteriostatic antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Apply 1-2 drops or a small amount (approximately 0.5 cm ribbon) into the affected eye(s) every 3-4 hours, or more frequently as needed. For severe infections, may be used every 2 hours. Not to exceed 6 times daily. Otic: Instill 3-4 drops into the affected ear(s) 2-3 times daily.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
None Documented
None Documented
Chloramphenicol: 1.5-4 hours in adults with normal hepatic function; prolonged to 3-7 hours in neonates and up to 15 hours in severe liver disease. Hydrocortisone: 1-2 hours.
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Renal: ~80-90% of chloramphenicol as inactive metabolites (glucuronide conjugate) and 5-10% unchanged. Biliary: <3% of unchanged drug. Fecal: minimal.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Category D/X
Category C
Corticosteroid
Corticosteroid